Table 2.
Medians (interquartile ranges; in pg/mL) of serum interleukin concentrations in the intervention arm of the Polyp Prevention Trial by their corresponding interleukin polymorphism (n = 808)
| Interleukin | Interleukin Concentrations (Median, IQR in pg/mL) | P Non | P for | ||
|---|---|---|---|---|---|
| Polymorphism | Param.* | Trend† | |||
| IL-1β -511 | C/C | C/T | T/T | ||
| Sample size | 319 | 359 | 78 | ||
| Baseline (T0) | 0.35 (0.22–0.63) | 0.37 (0.22–0.59) | 0.38 (0.21–0.74) | 0.93 | 0.40 |
| Intervention (T1,3) | 0.36 (0.23–0.59) | 0.38 (0.24–0.65) | 0.37 (0.25–0.61) | 0.74 | 0.82 |
| Change (T1,3-T0) | −.01 (−0.15–0.14) | 0.02 (−0.11–0.16) | 0.03 (−0.11–0.21) | 0.19 | 0.75 |
| IL-6 -174 | G/G | G/C | C/C | ||
| Sample size | 284 | 353 | 105 | ||
| Baseline (T0) | 1.83 (1.27–2.95) | 1.89 (1.36–2.72) | 2.03 (1.44–2.84) | 0.62 | 0.40 |
| Intervention (T1,3) | 1.95 (1.44–2.88) | 2.00 (1.44–2.80) | 1.90 (1.49–2.54) | 0.85 | 0.82 |
| Change (T1,3-T0) | 0.02 (−0.44–0.55) | 0.11 (−0.35–0.50) | −.01 (−0.70–0.54) | 0.52 | 0.72 |
| IL-8 -251 | T/T | A/T | A/A | ||
| Sample size | 187 | 378 | 179 | ||
| Baseline (T0) | 10.6 (7.95–13.5) | 10.4 (7.88–14.1) | 10.7 (8.05–14.9) | 0.63 | 0.23 |
| Intervention (T1,3) | 11.2 (8.39–15.7) | 10.5 (7.93–15.1) | 10.9 (8.41–16.2) | 0.38 | 0.45 |
| Change (T1,3-T0) | 0.50 (−2.17–3.08) | 0.19 (−2.09–2.38) | 0.49 (−1.73–2.82) | 0.67 | 0.75 |
| IL-10 -592 | C/C | C/A | A/A | ||
| Sample size | 432 | 275 | 62 | ||
| Baseline (T0) | 3.16 (2.07–5.59) | 3.36 (2.20–6.48) | 3.35 (1.96–4.89) | 0.53 | 0.16 |
| Intervention (T1,3) | 3.18 (2.09–5.59) | 3.31 (2.14–5.66) | 3.08 (2.25–5.33) | 0.80 | 0.26 |
| Change (T1,3-T0) | −.03 (−0.82–0.56) | −.16 (−0.96–0.50) | 0.04 (−0.49–0.83) | 0.14 | 0.29 |
| IL-10 -819 | C/C | C/T | T/T | ||
| Sample size | 444 | 279 | 66 | ||
| Baseline (T0) | 3.14 (2.09–5.51) | 3.42 (2.21–6.71) | 3.35 (1.98–4.89) | 0.29 | 0.07 |
| Intervention (T1,3) | 3.13 (2.13–5.55) | 3.34 (2.23–5.66) | 3.02 (2.22–5.23) | 0.72 | 0.24 |
| Change (T1,3-T0) | 0.00 (−0.82–0.58) | −.12 (−0.96–0.49) | 0.00 (−0.64–0.60) | 0.26 | 0.29 |
| IL-10 -1082 | A/A | A/G | G/G | ||
| Sample size | 221 | 409 | 147 | ||
| Baseline (T0) | 3.24 (2.02–5.94) | 3.44 (2.24–6.18) | 3.24 (2.02–5.27) | 0.29 | 0.29 |
| Intervention (T1,3) | 3.04 (2.15–5.58) | 3.35 (2.25–5.86) | 2.97 (2.00–5.09) | 0.46 | 0.17 |
| Change (T1,3-T0) | −.03 (−0.70–0.60) | −.07 (−1.01–0.58) | −.05 (−0.83–0.46) | 0.56 | 0.09 |
| IL-10 Haplotypea | A-C-C | G-C-C | G-T-A | ||
| Sample size | 143 | 269 | 322 | ||
| Baseline (T0) | 3.32 (2.01–5.27) | 3.18 (2.15–5.69) | 3.39 (2.18–6.48) | 0.38 | 0.06 |
| Intervention (T1,3) | 3.26 (2.35–5.78) | 3.31 (2.23–5.78) | 3.16 (2.01–4.88) | 0.53 | 0.16 |
| Change (T1,3-T0) | −.05 (−0.81–0.51) | −.03 (−0.93–0.62) | −.09 (−0.93–0.56) | 0.81 | 0.20 |
*
P values for differences in medians among the flavonol intake quartiles were calculated based on the Kruskal-Wallis test.
†
Median concentrations of each interleukin genotype were used to determine P for trend of the interleukin concentrations using a multiple regression model adjusting for age tertiles (<58, 58–66, >66 yrs), sex, race (Caucasian, non Caucasian), average BMI (<25, 25.0–29.9, ≥30 kg/m2), and current smoking status during the first 3 trial years.
a
Composed of 3 polymorphic sites: -1082 AA/G, -819 CC/T, and -592 CC/A.